Fig 1.
Among 2,189 incident dialysis patients, 1,015 patients were excluded. A total of 1,174 patients were finally analyzed. Abbreviations: CRC, clinical research center; ESRD, end-stage renal disease; HD, hemodialysis; HDL-C, high-density lipoprotein cholesterol; PD, peritoneal dialysis; TG, triglyceride.
Table 1.
Baseline demographics and clinical characteristics of subjects according to the AIP categories.
Table 2.
Laboratory data at 3 months after dialysis initiation according to the AIP categories.
Table 3.
Uni- and multivariate linear regression analysis of clinical and biochemical variables for higher AIP.
Table 4.
All-cause and cardiovascular death events according to the AIP categories.
Fig 2.
Hazard ratios of all-cause and cardiovascular mortality for AIP categories in 1,174 incident dialysis patients.
(A) all-cause mortality and (B) cardiovascular mortality. Model 1: adjusted for sex, age, diabetes mellitus, previous history of cardiovascular disease, dialysis modality, and body mass index; Model 2: Model 1+serum albumin, log hs-CRP, and residual urine volume. Abbreviations: AIP, atherogenic index of plasma; hs-CRP, high-sensitivity C-reactive protein.
Fig 3.
Adjusted hazard ratios of all-cause mortality for AIP categories in different subgroups.
(A) in 513 non-diabetic, (B) in 661 diabetic patients, (C) in 653 underweight to normal BMI patients, (D) in 521 overweight to obese patients, (E) in 740 HD, and (F) in 434 PD patients. Adjusted for age, sex, dialysis modality, modified Charlson comorbidity index, BMI, serum albumin, log hs-CRP, and residual urine volume. In subgroup analyses regarding HD and PD, dialysis modality was not adjusted. Abbreviations: AIP, atherogenic index of plasma; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein.